BrainsWay Ltd. (BWAY), the Israeli neurotechnology company whose NASDAQ-listed shares trade as an American depositary receipt (ADR), has drawn increasingly bullish analyst coverage as its Deep Transcranial Magnetic Stimulation (Deep TMS) platform gains commercial traction. The question for investors is whether the stock can climb to the roughly $19 level that a small group of analysts currently models.
BrainsWay is thinly covered by the sell side, which makes any "consensus" figure a product of just a handful of estimates rather than a broad institutional view. Three current, attributable price targets were reviewed. H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating with a $19 target in early November 2026, while BTIG's Sam Eiber maintained a Buy with a $20 target in October 2026, and Ladenburg Thalmann held an $18.80 target following the company's second-quarter report.
The arithmetic mean of those three figures is about $19.27, which rounds to a $19 central target. The low-to-high range of $18.80 to $20.00 is unusually tight, suggesting analysts broadly agree on the company's growth trajectory. Their reasoning centers on accelerating system shipments, expanding insurance reimbursement for the SWIFT accelerated protocol, and a growing recurring-revenue base. H.C. Wainwright's earlier target increase cited higher forward revenue estimates and the perceived value of BrainsWay's convertible loan investment in the private neurostimulation firm Neurolief. It is worth noting that this $19 figure is a calculated average of individual targets, not an officially published consensus number.
Shares closed near $11.64 in early November 2026 but slid to roughly $10.60 after BrainsWay reported third-quarter results, and have traded in a 52-week range of about $7.14 to $17.40. Reaching $19 from approximately $10.60 requires a gain of about 80%, which is a very large move even for a high-growth small-cap medical device company. Notably, the stock would first need to reclaim and exceed its 52-week high of $17.40.
The path would likely depend on continued double-digit revenue growth, further margin expansion, and progress on reimbursement and regulatory catalysts rather than a single quarter. BrainsWay shipped 130 Deep TMS systems in the third quarter, up 44% year over year, pushing its installed base past roughly 2,080 systems, and management raised full-year 2026 guidance to the upper end of its prior range with the potential to modestly exceed it.
BrainsWay's third quarter showed a fundamentally stronger business despite a headline EPS shortfall. Revenue rose 34% to $18.1 million, gross margin reached 78%, adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) nearly doubled to $3.9 million, and operating cash flow improved to $6.2 million. Remaining performance obligations reached approximately $85 million, up 31%, providing revenue visibility. Reimbursement is a central driver: more than 70 million U.S. lives now have access to SWIFT protocol coverage, well ahead of the company's earlier target, and management said roughly half of new demand involves SWIFT. A strong cash position of about $63 million and FDA-cleared indications for major depressive disorder, obsessive-compulsive disorder, and smoking addiction support the growth narrative.
The most immediate obstacle is execution relative to expectations. BrainsWay reported third-quarter EPS of $0.05, missing the roughly $0.09 consensus, as operating expenses rose 29% and share-based compensation more than doubled. Valuation is another consideration: with a trailing P/E (price-to-earnings) ratio around 46 and a small market capitalization, the stock can de-rate quickly if growth disappoints. The FDA clearance for comorbid PTSD and major depressive disorder remains under review, and order flow from newer partnerships can be lumpy. As a thinly traded small cap, the stock is also vulnerable to outsized moves in either direction on limited news.
The $17.40 level, the stock's 52-week high, is the most relevant near-term resistance, followed by the psychological $20 round number that aligns with the highest analyst target. On the downside, the post-earnings $10 area and the 52-week low near $7.14 are the notable support zones. A sustained move toward $19 would require the shares to break decisively above the prior 52-week high and hold that level as new support.
Analyst price targets typically reflect a roughly 12-month research horizon, though the three covering firms do not publish identical timing assumptions. Investors should watch quarterly earnings and guidance, system shipment and RPO trends, margin progression, and any update on the PTSD/MDD regulatory review. Reimbursement expansion for SWIFT and OCD coverage, along with analyst target revisions following each quarterly report, are the most likely catalysts to move the target debate.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile small-cap name such as BrainsWay, this kind of systematic screening can help traders discover opportunities, monitor positions, and spot shifting trends more efficiently than manual chart review. Traders looking for an objective, data-driven layer on top of fundamental research may find these signals a useful complement to their process.
The $19 central target represents a calculated average of three Buy-rated analyst targets, ranging narrowly from $18.80 to $20.00. From a post-earnings price near $10.60, that implies an upside of roughly 80%, which is a substantial hurdle. The bull case rests on accelerating system placements, a growing recurring-revenue backlog, margin expansion, and reimbursement gains, while the bear case centers on the EPS miss, rising costs, a pending regulatory decision, and a rich valuation for a small-cap device maker. Whether BrainsWay can reach $19 will ultimately depend on whether it sustains its growth and margin trajectory while converting its reimbursement momentum into durable profitability. No analyst target, including this calculated mean, is a guarantee of future performance.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, BWAY has been loosely correlated with DCTH. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if BWAY jumps, then DCTH could also see price increases.
| Ticker / NAME | Correlation To BWAY | 1D Price Change % | ||
|---|---|---|---|---|
| BWAY | 100% | +5.34% | ||
| DCTH - BWAY | 34% Loosely correlated | +8.31% | ||
| MBOT - BWAY | 33% Poorly correlated | +5.71% | ||
| ISRG - BWAY | 31% Poorly correlated | -0.11% | ||
| TCMD - BWAY | 31% Poorly correlated | +1.92% | ||
| QSI - BWAY | 30% Poorly correlated | -0.78% | ||
More | ||||
| Ticker / NAME | Correlation To BWAY | 1D Price Change % |
|---|---|---|
| BWAY | 100% | +5.34% |
| Health Services category (239 stocks) | 5% Poorly correlated | +0.54% |
| Medical/Nursing Services category (138 stocks) | 5% Poorly correlated | +1.05% |